🇺🇸 FDA
Patent

US 11730150

Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy

granted A61KA61K49/0008

Quick answer

US patent 11730150 (Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy) held by REGENERON PHARMACEUTICALS, INC. expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K49/0008